-
-
-
-
-
-
-
Merck and Eisai trial for kidney cancer combination therapy fails endpoints
-
-
-
-
-
-
-
KEYTRUDA Plus WELIREG Shows 28% Reduction in Cancer Recurrence Risk
-
-
-
-
-
-
-
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Na
-
-
-
-
-
-
-
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
-
-
-
-
-
-
-
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally
-
-
-
-
-
-
-
FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
-
-
-
-
-
-
-
Merck (MRK) Provides Update on Phase 3 KEYNOTE-B21 Trial of KEYTRUDA Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With
-
15,819 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

